Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial

Eytan M. Stein, Amir T. Fathi, Courtney D. DiNardo, Daniel A. Pollyea, Gail J. Roboz, Robert H. Collins, Mikkael A. Sekeres, Richard M. Stone, Eyal C. Attar, Mark G. Frattini, Alessandra Tosolini, Qiang Xu, Wendy L. See, Kyle J. MacBeth, Stéphane de Botton, Martin S. Tallman, Hagop M. Kantarjian